Komohara Yoshihiro, Horlad Hasita, Ohnishi Koji, Ohta Kazutaka, Makino Keishi, Hondo Hiroaki, Yamanaka Ryuya, Kajiwara Koji, Saito Takafumi, Kuratsu Jun-ichi, Takeya Motohiro
Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Japan.
J Clin Exp Hematop. 2011;51(2):93-9. doi: 10.3960/jslrt.51.93.
Primary central nervous system lymphoma (PCNSL) is one of the most aggressive malignant lymphomas with a median survival of less than 20~40 months. Interest in signal transducer and activator of transcription 3 (Stat3) has increased during the past decade because Stat3 activation was found to contribute to tumor progression by inducing angiogenesis, immunosuppression, and metastasis. We previously demonstrated a significant correlation between Stat3 activation in tumor cells and infiltrating anti-inflammatory (M2) macrophages. Here, we focused on the phenotypes of infiltrating macrophages/microglial cells and Stat3 activation in PCNSL cells. The correlation of Stat3 activation or density of M2 macrophage infiltration with patient prognosis was also evaluated. We performed immunostaining for CD68, CD163, CD204, and pStat3 using paraffin-embedded PCNSL specimens obtained from 43 patients. CD163 and CD204 served as markers of the M2 phenotype. Dense infiltration of CD68(+) macrophages was found in all samples. High numbers of CD163(+) and CD204(+) M2 macrophages/microglial cells were observed in 29 and 25 cases, respectively. Stat3 activation in lymphoma cells was enhanced in the patients who showed denser infiltration of CD163(+) macrophages/microglial cells in tumor tissues. In vitro co-culture experiment to investigate cell-cell interactions between macrophages and lymphoma cells found that Stat3 in lymphoma cells was strongly activated by co-culture with macrophages. Numbers of CD68(+), CD163(+), and CD204(+) tumor-associated macrophages/microglial cells (TAMs) and Stat3 activation in lymphoma cells were not correlated with prognosis. However, because Stat3 involvement in tumor development was demonstrated in several malignant tumors, our present finding that cell-cell interactions of M2 macrophage/microglial cells with lymphoma cells induced Stat3 activation may provide novel insights into PCNSL pathogenesis.
原发性中枢神经系统淋巴瘤(PCNSL)是最具侵袭性的恶性淋巴瘤之一,中位生存期不到20至40个月。在过去十年中,对信号转导和转录激活因子3(Stat3)的关注有所增加,因为发现Stat3激活通过诱导血管生成、免疫抑制和转移促进肿瘤进展。我们之前证明肿瘤细胞中的Stat3激活与浸润的抗炎(M2)巨噬细胞之间存在显著相关性。在此,我们重点研究了PCNSL细胞中浸润的巨噬细胞/小胶质细胞的表型以及Stat3激活情况。还评估了Stat3激活或M2巨噬细胞浸润密度与患者预后的相关性。我们使用从43例患者获得的石蜡包埋PCNSL标本对CD68、CD163、CD204和pStat3进行了免疫染色。CD163和CD204作为M2表型的标志物。在所有样本中均发现CD68(+)巨噬细胞密集浸润。分别在29例和25例中观察到大量CD163(+)和CD204(+) M2巨噬细胞/小胶质细胞。在肿瘤组织中CD163(+)巨噬细胞/小胶质细胞浸润更密集的患者中,淋巴瘤细胞中的Stat3激活增强。为研究巨噬细胞与淋巴瘤细胞之间细胞间相互作用的体外共培养实验发现,淋巴瘤细胞中的Stat3通过与巨噬细胞共培养而被强烈激活。CD68(+)、CD163(+)和CD204(+)肿瘤相关巨噬细胞/小胶质细胞(TAM)的数量以及淋巴瘤细胞中的Stat3激活与预后无关。然而,由于在几种恶性肿瘤中已证明Stat3参与肿瘤发展,我们目前发现M2巨噬细胞/小胶质细胞与淋巴瘤细胞的细胞间相互作用诱导Stat3激活,这可能为PCNSL发病机制提供新的见解。